EUVIMEDEUVIMED entdecken
Crossref

Clinicopathologic and Molecular Characteristics of HER2 (ERBB2)-Altered Non–Small Cell Lung Cancer: Implications for Precision Medicine

Yurimi Lee, Boram Lee, Yoon-La Choi, Dong-Wook Kang, Joungho Han

Modern Pathology · 2024-06 · 37 (6) · 100490

DOI: 10.1016/j.modpat.2024.100490 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Modern Pathology, 2024-06. Verfasst von Yurimi Lee und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology and Translational Genomics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea; Departmen…. Hauptthemen laut MEDLINE: Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Erb-b2 Receptor Tyrosine Kinases, Precision Medicine. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 47 Literaturangaben. Gefördert von: Samsung Medical Center, Sungkyunkwan University, Ministry of Science, ICT and Future Planning, National Research Foundation of Korea.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The heterogeneous relationship between protein expression, amplification, and mutations in human epidermal growth factor receptor 2 (HER2) in non-small cell lung cancer (NSCLC) and the optimal methods for detecting these alterations remain unclear. We aimed to elucidate the clinicopathological and molecular characteristics of HER2-altered NSCLC and investigate practical approaches for identifying patients who might benefit from HER2-targeted therapies. Using next-generation sequencing data from 1680 individuals, we searched for patients with HER2-altered NSCLCs, including amplifications and mutations. Clinicopathological data and tissue slides were reviewed. Immunohistochemistry (IHC) and silver in situ hybridization were performed according to the American Society of Clinical Oncology/College of American Pathologists guidelines. Our analysis identified 89 (5.3%) patients with HER2-altered NSCLCs, comprising 30 (1.8%) with amplification and 59 (3.6%) mutations, and they were compared with 165 control patients. Of the 59 HER2-mutated cases, 52 harbored tyrosine kinase domain (TKD) mutations, primarily HER2 exon 20 insertions. HER2 TKD alterations were associated with younger age, female sex, nonsmoking status, adenocarcinoma with a micropapillary pattern, lung-to-lung metastasis, and poor overall survival. The 33 patients with TKD mutations and 3 with non-TKD point mutations showed incomplete or complete membranous HER2 immunoreactivity (1+ and 2+, 61.07%). Six patients exhibiting amplifications had an IHC score of ≤2+ despite their high copy numbers and concomitantly displayed other actionable EGFR, KRAS, SMARCA4, and other HER2 mutations. These HER2-altered NSCLCs with molecular coalterations showed heterogeneous patterns through HER2 IHC and silver in situ hybridization. Therefore, next-generation sequencing should be used to identify HER2 mutations in patients with NSCLC who present with concomitant alterations. In addition, the above clinicopathological characteristics and HER2 IHC results can be valuable determinants for identifying patients with HER2-altered NSCLC. These insights hold promise for the development of more effective diagnostic and therapeutic strategies for this complex subset of NSCLC patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung NeoplasmsCarcinoma, Non-Small-Cell LungErb-b2 Receptor Tyrosine KinasesPrecision MedicineMutationBiomarkers, TumorHumansFemaleMaleMiddle AgedAgedAdultAged, 80 and overImmunohistochemistryHigh-Throughput Nucleotide SequencingGene Amplification

Stichwörter der Autor:innen

HER2 amplificationHER2 mutationnext-generation sequencingnon–small cell lung cancertyrosine kinase domain mutation

Substanzen

Erb-b2 Receptor Tyrosine KinasesBiomarkers, TumorERBB2 protein, human

Autor:innen und Institutionen

  • Department of Pathology and Translational Genomics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea; Department of Pathology, Chungnam National University College of Medicine, Daej…
  • Department of Pathology and Translational Genomics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea. Electronic address: boram.lee.1103@gmail.com.
  • Department of Pathology and Translational Genomics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea; Department of Health Sciences and Technology, SAIHST, Sungkyunkwan University,…
  • Department of Pathology, Chungnam National University College of Medicine, Daejeon, South Korea.
  • Department of Pathology and Translational Genomics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.

Förderung

  • Samsung Medical Center, Sungkyunkwan University
  • Ministry of Science, ICT and Future Planning
  • National Research Foundation of Korea

Zitieren

APA

Lee, Y., Lee, B., Choi, Y. L., Kang, D. W., & Han, J. (2024). Clinicopathologic and Molecular Characteristics of HER2 (ERBB2)-Altered Non–Small Cell Lung Cancer: Implications for Precision Medicine. Modern Pathology, 37(6), 100490. https://doi.org/10.1016/j.modpat.2024.100490

Vancouver

Lee Y, Lee B, Choi YL, Kang DW, Han J. Clinicopathologic and Molecular Characteristics of HER2 (ERBB2)-Altered Non–Small Cell Lung Cancer: Implications for Precision Medicine. Modern Pathology. 2024;37(6):100490. doi:10.1016/j.modpat.2024.100490

BibTeX
@article{Lee2024,
  author = {Lee, Yurimi and Lee, Boram and Choi, Yoon-La and Kang, Dong-Wook and Han, Joungho},
  title = {Clinicopathologic and Molecular Characteristics of HER2 (ERBB2)-Altered Non–Small Cell Lung Cancer: Implications for Precision Medicine},
  journal = {Modern Pathology},
  year = {2024},
  volume = {37},
  number = {6},
  pages = {100490},
  doi = {10.1016/j.modpat.2024.100490}
}
Kostenlos starten →